Meeting
2022 ASCO Annual Meeting
Multicenter phase II study of abemaciclib and ramucirumab in metastatic esophageal/gastroesophageal junction carcinoma.
Authors
Ronan Joseph Kelly
Baylor University Medical Center, Dallas, TX
Ronan Joseph Kelly , Vincent K. Lam , Scott Paulson , Natalie Settele , Oghenevovwero Sido , Valsamo Anagnostou , Moses S. Raj , Ali Hussainy Zaidi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT04921904
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4169)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4169
Abstract #
TPS4169
Poster Bd #
150a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
First Author: Manish R. Patel
Poster
2022 ASCO Annual Meeting
postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.
First Author: Kevin Kalinsky
Poster
2020 Gastrointestinal Cancers Symposium
Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149.
First Author: Nataliya Volodymyrivna Uboha
Poster
2019 ASCO Annual Meeting
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.
First Author: Laura Spring